DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

A trial of isocarboxazid in the treatment of bulimia nervosa.

Author(s): Kennedy SH, Piran N, Warsh JJ, Prendergast P, Mainprize E, Whynot C, Garfinkel PE

Affiliation(s): Department of Psychiatry, University of Toronto, Ontario, Canada.

Publication date & source: 1988-12, J Clin Psychopharmacol., 8(6):391-6.

Publication type: Clinical Trial; Controlled Clinical Trial; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

Eighteen women completed a double-blind, placebo-controlled crossover study designed to investigate the effects of isocarboxazid in the treatment of bulimia nervosa. There was a significant reduction in binge eating and vomiting during isocarboxazid treatment. Response was not influenced by either the presence or absence of current major depression or personality disorder. There were no serious adverse effects from this monoamine oxidase inhibitor therapy, although over 50% of patients elected to discontinue isocarboxazid 1 year after the study.

Page last updated: 2007-10-18

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017